Celltrion to select lead antibody candidates to fight COVID-19
Posted: 6 April 2020 | Victoria Rees (Drug Target Review) | No comments yet
Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.


Celltrion has announced its transition to its second phase of development for an antiviral treatment to fight the novel coronavirus (COVID-19) pandemic.
Last month, the company completed its first phase of research, securing 300 different types of antibodies that recognise and block the Spike (S) protein that the virus uses to enter human cells. The library of antibodies was created using the blood of recovered patients in Korea.
In co-operation with the Korea Centers for Disease Control and Prevention (KCDC), Celltrion will be screening the antibodies to find the ones most effective in neutralising SARS-CoV-2, the virus responsible for COVID-19. The company says it anticipates the candidate screening for the therapeutic monoclonal antibody (mAb) will be complete by mid-April, sooner than originally expected.
AI-powered drug discovery: Accelerating the development of life-saving therapies
18 September 2025 | 14:00PM BST | FREE Webinar
Join this webinar to learn how AI is accelerating early-stage drug discovery and improving target identification, practical strategies for applying AI effectively within your organisation and to ask your questions to our industry expert! Dr Remco Jan Geukes Foppen will share practical insights into how AI is being applied across the pharmaceutical sector, helping teams move faster and make better-informed decisions. With experience spanning data management, image analysis, bioinformatics, and machine learning in clinical research, he brings both deep technical expertise and strategic understanding of real-world challenges.
Register Now – It’s Free!
Ki-Sung Kwon, Head of R&D Unit at Celltrion said: “Once we have selected the one that most effectively neutralises the COVID-19 virus among hundreds of the screened antibodies, we will roll out mass production of the therapeutic antibody treatment, with a view to starting human trials this July. Due to the urgent need for a COVID-19 antiviral treatment, we have expedited the overall development process of our antiviral therapy to help infected patients fight this emerging virus and halt further spread of the disease.”
Celltrion also plans to develop a ‘super antibody’ that can neutralise multiple coronavirus-related strains such as those causing COVID-19 and severe acute respiratory syndrome (SARS), enabling further protection against potential mutations.
The company also aims to launch a rapid self-testing diagnostic kit which is designed to show results within 15-20 minutes.
Related topics
Antibodies, Antibody Discovery, Drug Discovery, Drug Leads, Hit-to-Lead, Screening
Related conditions
Coronavirus, Covid-19
Related organisations
Celltrion
Related people
Ki-Sung Kwon